Christopher M DeGiorgio1, Scott E Krahl. 1. Department of Neurology, David Geffen-UCLA School of Medicine, 710 Westwood Plaza, Los Angeles, CA 90095, USA. cmd@mednet.ucla.edu
Abstract
PURPOSE OF REVIEW: The purpose of this review is to provide an evidence-based update on the neurostimulation options available for patients with drug-resistant epilepsy in the United States and in European countries. RECENT FINDINGS: The field of neurostimulation for epilepsy has grown dramatically since 1997, when vagus nerve stimulation became the first device to be approved for epilepsy by the US Food and Drug Administration (FDA). New data from recently completed randomized controlled trials are available for deep brain stimulation of the anterior thalamus, responsive neurostimulation, and trigeminal nerve stimulation. Although vagus nerve stimulation is the only device currently approved in the United States, deep brain stimulation and responsive neurostimulation devices are awaiting FDA approval. Deep brain stimulation, trigeminal nerve stimulation, and transcutaneous vagus nerve stimulation are now approved for epilepsy in the European Union. In this article, the mechanisms of action, safety, and efficacy of new neurostimulation devices are reviewed, and the key advantages and disadvantages of each are discussed. SUMMARY: The exponential growth of the field of neuromodulation for epilepsy is an exciting development; these new devices provide physicians with new options for patients with drug-resistant epilepsy.
PURPOSE OF REVIEW: The purpose of this review is to provide an evidence-based update on the neurostimulation options available for patients with drug-resistant epilepsy in the United States and in European countries. RECENT FINDINGS: The field of neurostimulation for epilepsy has grown dramatically since 1997, when vagus nerve stimulation became the first device to be approved for epilepsy by the US Food and Drug Administration (FDA). New data from recently completed randomized controlled trials are available for deep brain stimulation of the anterior thalamus, responsive neurostimulation, and trigeminal nerve stimulation. Although vagus nerve stimulation is the only device currently approved in the United States, deep brain stimulation and responsive neurostimulation devices are awaiting FDA approval. Deep brain stimulation, trigeminal nerve stimulation, and transcutaneous vagus nerve stimulation are now approved for epilepsy in the European Union. In this article, the mechanisms of action, safety, and efficacy of new neurostimulation devices are reviewed, and the key advantages and disadvantages of each are discussed. SUMMARY: The exponential growth of the field of neuromodulation for epilepsy is an exciting development; these new devices provide physicians with new options for patients with drug-resistant epilepsy.
Authors: Hermann Stefan; Gernot Kreiselmeyer; Frank Kerling; Katrin Kurzbuch; Christophe Rauch; Marcel Heers; Burkhard S Kasper; Thilo Hammen; Martina Rzonsa; Elisabeth Pauli; Jens Ellrich; Wolfgang Graf; Rüdiger Hopfengärtner Journal: Epilepsia Date: 2012-05-03 Impact factor: 5.864
Authors: Heberto Suarez-Roca; Rebecca Y Klinger; Mihai V Podgoreanu; Ru-Rong Ji; Martin I Sigurdsson; Nathan Waldron; Joseph P Mathew; William Maixner Journal: Anesthesiology Date: 2019-04 Impact factor: 7.892
Authors: G Meneses; M Bautista; A Florentino; G Díaz; G Acero; H Besedovsky; D Meneses; A Fleury; A Del Rey; G Gevorkian; G Fragoso; E Sciutto Journal: J Inflamm (Lond) Date: 2016-10-29 Impact factor: 4.981
Authors: Sarah Feldt Muldoon; Fabio Pasqualetti; Shi Gu; Matthew Cieslak; Scott T Grafton; Jean M Vettel; Danielle S Bassett Journal: PLoS Comput Biol Date: 2016-09-09 Impact factor: 4.475
Authors: Lilit Mnatsakanyan; Sumeet Vadera; Christopher W Ingalls; Jie Zheng; Mona Sazgar; Frank P Hsu; Jack J Lin Journal: Epilepsy Behav Case Rep Date: 2017-06-17